Attached files
file | filename |
---|---|
10-K - FORM 10-K - REGENERX BIOPHARMACEUTICALS INC | c14810e10vk.htm |
EX-31.2 - EXHIBIT 31.2 - REGENERX BIOPHARMACEUTICALS INC | c14810exv31w2.htm |
EX-31.1 - EXHIBIT 31.1 - REGENERX BIOPHARMACEUTICALS INC | c14810exv31w1.htm |
EX-23.1 - EXHIBIT 23.1 - REGENERX BIOPHARMACEUTICALS INC | c14810exv23w1.htm |
EX-32.2 - EXHIBIT 32.2 - REGENERX BIOPHARMACEUTICALS INC | c14810exv32w2.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of RegeneRx Biopharmaceuticals, Inc. (the Company) on Form
10-K for the fiscal year ended December 31, 2010, as filed with the Securities and Exchange
Commission on the date hereof (the Report), I, J.J. Finkelstein, Chief Executive Officer of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
||
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company as of and for the periods presented in this report. |
This certification accompanies this Report to which it relates, shall not be deemed filed with
the Securities and Exchange Commission and is not to be incorporated by reference into any filing
of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of
1934, as amended (whether made before or after the date of the Report), irrespective of any general
incorporation language contained in such filing.
Date: March 31, 2011
/s/ J.J. Finkelstein | ||||
J.J. Finkelstein | ||||
President and Chief Executive Officer (Principal Executive Officer) |
||||